Bio-innovation: Focusing on Cancer Diagnosis and Treatment, Empowering Health Business

Recently, Wuhan Bio-innovation Technology announced the completion of tens of millions of seed round financing. This financing was jointly invested by Dongke Chuangxing and Wuhan Institute of Biotechnology. The funds obtained will be used to promote the research and development and registration inspection of various product pipelines of the company, so as to accelerate the launch of product pipelines and the acquisition of IND clinical approval documents.

Founded in June 2021, Wuhan Bio-innovation Technology is committed to the screening and verification of new cancer immunotherapy sites, preclinical research of antibody drugs and cell therapy drugs, and provides advanced immunotherapy diagnosis and services for tumors. At the same time, it is also actively deploys peptide drug research and development. In January 2022, the company signed a scientific research cooperation agreement with Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology to promote the smooth implementation of cooperation projects and the transformation of potential achievements.

At present, the company has gathered a large number of experts, professors and industrialization teams from the fields of oncology, immunology and medical testing. In the technical team, 6 people have doctoral degrees, 5 people have overseas study experience, and 4 people are selected into the national high-level talent plan. At present, the company has the original innovation capability of cancer companion diagnosis.

Based on the current status of malignant tumor treatment and the needs of patients, Bio-innovation Technology has independently developed two core products. Among them, the PD-L1 companion diagnostic kit “Innokang” greatly improves the detection specificity on the basis of maintaining a high detection sensitivity, so that patients with cancer can be diagnosed more accurately, and thus have the hope of cure. The new anti-tumor cell metastasis polypeptide drug “Innotex” can fundamentally control the problem of pleural and ascites by inhibiting the activity and metastasis of cancer cells, and prolong the life cycle of patients with advanced cancer.

The PD-1/PD-L1 companion diagnostic in vitro diagnostic reagents independently developed by Bio-innovation Technology can greatly improve the sensitivity of the efficacy of anti-PD-1/L1 immunotherapy, so as to more accurately identify the real benefits of PD-1/ L1 immunotherapy patients. After effective verification in lung cancer, “Innokang” predicts the efficacy of anti-PD-1/L1 immunotherapy with a sensitivity of 93%, which is much higher than the sensitivity of other existing companion diagnostic products, which is less than 60%.

Cancerous pleural and ascites is one of the common complications of terminal cancer. Severe pleural and ascites can even be life-threatening. Often in clinical cases, the survival of patients with pleural ascites is less than 6 months. The current mainstream methods for the treatment of cancerous pleural ascites include diuretic therapy and hyperthermic perfusion therapy, but none of them can solve the problem from the root cause.

By inhibiting the activity and metastasis of cancer cells, the new peptide drug “Innotai” independently developed by the company can fundamentally control pleural and ascites, prolong the life cycle of patients with advanced cancer, relieve the pain of patients, and improve the quality of life.

Li Runqing, general manager of Bio-innovation Technology, said: “Since the establishment of the company, our company has been committed to transforming clinically proven technological innovations into industrial achievements in precision immunotherapy, so that patients with terminal cancer still have hope of cure. In the future, we will also continue to focus on the needs of cancer diagnosis and treatment, practice the concept of precision treatment, and help the development of human health.”